Blog
August 4, 2025
Most workplace biosafety programs fail for the same 3 reasons— and each one can expose your organization to unnecessary risk.
July 25, 2025
The #1 reason irritation testing gets rejected? You’re using the wrong exposure route. We’ve reviewed dozens of irritation studies that looked solid—until they reached regulators. The […]
July 3, 2025
When it comes to medical device testing, more isn’t always better. One of the biggest mistakes we see? Teams defaulting to comprehensive test panels — even […]
June 26, 2025
The National Institutes of Health (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program is part of a congressionally funded effort to encourage and speed the development of new drugs for rare and neglected diseases. The federal budget for fiscal 2009 dedicated $24 million to establish this initiative. TRND will bridge the wide gap in time and resources that often exists between basic research and human testing of new drugs. The effort is grounded in, but aims to improve upon, existing processes for drug development in the pharmaceutical industry.
